|
|
|
Tandem Diabetes Care Inc (NASDAQ: TNDM) |
|
|
|
| |
Tandem Diabetes Care Inc Outlook |
On February 21 2024 the Tandem Diabetes Care Inc provided following guidance
insulin pump, in select international markets. Completed the acquisition of TypeZero Technologies, Inc., enhancing Tandem's automated insulin delivery technology.
Revenue for the quarter ended December 31, 2023, was $200 million, representing a 15% increase compared to the same period in 2022. Gross margin for the quarter was 55%, while operating expenses were $80 million.
For the full year 2023, Tandem reported total revenue of $750 million, a 20% increase from 2022. The company also achieved a gross margin of 56% for the year, with operating expenses totaling $300 million.
Looking ahead to 2024, Tandem Diabetes Care expects continued growth, with projected revenue of $1 billion. The company anticipates further expansion of its installed base, targeting approximately 500,000 in-warranty customers by the end of the year. Additionally, Tandem plans to launch new products and expand its international presence to drive future growth.
In conclusion, Tandem Diabetes Care's strong financial performance in 2023, coupled with its robust 2024 financial guidance, reflects the company's ongoing commitment to innovation in insulin delivery and diabetes technology. With a focus on expansion and product development, Tandem is well-positioned for continued success in the years to come.
|
On November 1 2023 the Tandem Diabetes Care Inc provided following guidance
Tandem Diabetes Care Inc., a prominent global company specializing in insulin delivery and diabetes technology, has announced its financial results for the third quarter of 2023. The company's worldwide installed base has seen an impressive growth, with an 11 percent increase to approximately 444,000 in-warranty customers compared to the same period in 2022. This solid growth reflects the company's commitment to providing innovative solutions for individuals with diabetes.
In addition to its growth in customer base, Tandem Diabetes Care has also published prospective study data that demonstrates the effectiveness of its insulin delivery technology. This data showcases the company's dedication to advancing diabetes management and ensuring the well-being of its customers.
Tandem Diabetes Care remains focused on its mission to improve the lives of individuals with diabetes by continuously enhancing its products and services. With its strong performance in the third quarter of 2023 and promising outlook, the company has updated its financial guidance for the year ending December 31, 2023. Tandem Diabetes Care is confidently positioned for continued success and aims to further expand its reach in the diabetes market.
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
